Technology That Boldly Redefines
the EP Lab

Bold Solutions to Challenge AFib

Bold Solutions to Challenge AFib

Reinventing the Technology You Rely On Everyday

A solutions-based approach to innovation, Abbott’s EP portfolio is designed to improve your procedure experience. Our approach to technology helps physicians deliver better outcomes faster by focusing on three key factors:


Get In and Out of Your Lab in Less Time

Bold technology lets you treat more patients in less time. With Advisor™ HD Grid Mapping Catheter, Sensor Enabled™, procedure times are reduced by an average of 34 minutes versus CMCs1


 alarm clock icon

Know You are Doing it Right the First Time

Efficiency is not just about reduction in procedure times. Bold technology should also promise less repeat procedures and reduced all-cause events. Advisor™ HD Grid Mapping Catheter has shown a 14% reduction in redo procedures compared to CMCs2 and TactiCath™ Ablation Catheter, SE results in decreased healthcare utilization by reducing all-cause annual event rates by more than 53%3


 Reduction percentages

Exposure to Radiation Matters

With no increase to procedure time, the use of our mapping system is associated with a considerable reduction in Fluoroscopy time4 , radiation dosage, and laboratory staff radiation dosage.5


Minutes of reduced AFIB Fluoro time


Boldness in treating AFib requires technology that never sacrifices accuracy or efficiency. Abbott’s EP portfolio delivers both.


Redefine signal quality when paired with a best-in-class high density mapping catheter that improves the signal to noise ratio with a noise floor of 0.01 mV6



Accurate contact force matters during your ablation procedures. TactiCath™ Contact Force Catheter, Sensor Enabled™ has shown 6x greater accuracy in lateral orientation for contact force ablation than the competition.6,7

Patient Outcomes

Your end goal is for your patients to be well. Abbott’s focus on creating technologies that are efficient and accurate gives you the tools you need to boldly redefine patient outcomes and change your patients’ lives. Bold solutions to challenge AFib is –


Freeing Your Patients From Atrial Arrhythmias

12-month freedom from atrial
arrhythmias with Advisor HD Grid
Mapping Catheter, Sensor Enabled2

  grid percentages

Freedom of arrhythmia at 12 months
with Agilis NxT Steerable Sheath8

 Graph showing percentages of patients free of arrhythmia


Driving clinical success in Paroxysmal and Persistent AFib

  • Achieving an 82.2% clinical success rate for paroxysmal AFib at one year9
  • And a 90% symptomatic success rate at 15 months - using the TactiCath Ablation Catheter, Sensor Enabled9

Improved quality of life for patients at least 12 months following ablation10

 Paroxysmal and Persistent percentages

Free Your Patients From the Use of OACS for Stroke Risk Reduction

Ischemic stoke rate reduced by 67%
compared to predicted risk11

 Graph showing reduction in Ischemic stroke rate

With the Amplatzer™ Amulet™ Left Atrial Appendage Occluder (LAAO) you do both – not only delivering a 67% lower stroke rate, but also allowing 8 out of 10 patients to be discharged without OACs.12 Amplatzer Amulet LAAO is the only FDA-approved LAAO that does not require use of OACs at discharge.


Clinical support that elevates your
practice to meet today's challenges

  Heart icon


Partnerships that drive
impact for the EP community

 people icon





  1. Abbott. Report on file. 90299533
  2. Day, J. D., Crandall, B., Cutler, M., Osborn, J., Miller, J., Mallender, C., & Lakkireddy, D. (2020). High Power Ultra Short Duration Ablation with HD Grid Improves Freedom from Atrial Fibrillation and Redo Procedures Compared to Circular Mapping Catheter. Journal of Atrial Fibrillation, 13(2).
  3. Persist-End Final Clinical Study Report (Abbott report CL1013884).
  4. Olson N, Lo M, Zahwe F, Gururaj A, Martel JA, Bernard ML, Tao C and Venkataraman R. The effect of dynamic mapping data on procedure efficiency in radiofrequency ablation of patients with atrial fibrillation. Abstracts from the 26th Annual International Atrial Fibrillation Symposium. Journal of Cardiovascular Electrophysiology. 2021;32:1467-1515.
  5. Abbott. Data on File. Document 90114565.
  6. Bourier, F., Gianni, C., Dare, M., Deisenhofer, I., Hessling, G., Reents, T., . . . Al-Ahmad, A. (2017). Fiberoptic contact-force sensing electrophysiological catheters: how precise is the technology? Journal of Cardiovascular Electrophysiology, 28(1), 109-114.
  7. Bourier F, Deisenhofer I, Hessling G, et al. Contact-force sensing electrophysiological catheters: How accurate is the technology? [Abstract PO03-170]. Presentation at HRS 2016, San Francisco, CA, May 4-7, 2016. Heart Rhythm. 2016;13(5 Suppl 1):S318-S319.
  8. Abbott. Data on File. Document 90569806.
  9. Lo MY, Sanders P, Sommer P, Kalman JM, Siddiqui UR, Sundaram S, Piorkowski C, Olson N, Madej SM and Gibson DN. Safety and Effectiveness of a Next-Generation Contact Force Catheter. JACC: Clinical Electrophysiology. 2021;0.
  10. Mansour, M. (2014) TOCCASTAR: Preliminary Results of the First Prospective Randomized Study of a Contact Force Sensing Ablation Catheter for the Treatment of Paroxysmal AF. Presented at HRS 2014. San Francisco, California.
  11. Hildick Smith D et al, Left atrial appendage occlusion with the Amplatzer Amulet device: full results of the prospective global observational study; European Heart Journal 2020;41(30):2894-2901.
  12. Amplatzer Amulet LAA Occluder Instructions for Use.

MAT-2208731 v1.0